I was going to ask Alan about it. In the recent quarterly they mention that the supply is an easily scalable but that is a relative term. If the drugs are successful in achieving their endpoints, and the revenues and profits justify it either BP will acquire CU6 and build the backend given their global presence and reach, or other participants in the cyclotron/ rhoodotron may do so as well, ie if the demand is there the supply will come.
Research/Valuation, page-4
-
- There are more pages in this discussion • 528 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.86 |
Change
0.130(2.75%) |
Mkt cap ! $1.514B | |||
| Open | High | Low | Value | Volume |
| $4.66 | $4.89 | $4.57 | $3.779M | 795.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2500 | $4.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.87 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |